MM-197: Survival Rate of Multiple Myeloma (MM) Patients in Armenia: A Retrospective Analysis in Multiple Myeloma at a Single Institution

Context: MM is the second most commonly diagnosed hematological neoplasm over the world. MM primarily affects the elderly and is typically diagnosed between the ages of 65-74 years and characterized by severe bone, blood, and renal complications, impacting therapy choices and quality of life. Objective: The aim of the current study was a comprehensive analysis of MM, i.e., their prevalence, incidence, and survival rates in Armenia for the period of 2006-2020. Setting: The main data source for this study was outpatient and dispensary cards, hospitalization journals, as well as clinical data from the Register of Blood Diseases of the Hematology Center after. Prof. R. Yeolyan. This information has been supplemented by the data from National Oncological Centre after V.A. Fanarjyan, as well as from death registration service at Ministry of Justice RA. Results: We analyzed the data of 589 (48.2% female and 51.8% male) patients with MM registered in Armenian Hematology Center of the Ministry of Health of the Republic of Armenia from 2006 to 2020. The median age was 60.6 years. Data analysis showed that during the reported time period, the increase of the MM incidence was 1.23 per 100 000 population. In comparison to our earlier results, a significant increase in incidence of MM was found. The low five-year survival rates were beaten in groups of patients who initially refused therapy and/or were diagnosed already in higher ISS stage for this disease. Among patients receiving therapy, the best survival rates were beaten on MP, VAD protocols, and VCD and transplantation. The median survival for ISS stage II disease was 26 months, stage III disease 7 months, and stage I disease 20 months. Conclusions: In general, the results of treatment in the Armenian population with MM were comparable with the data of the total European cohort. Survival rate seems to be better among younger patients than in older ones, even with lower ISS stage of this disease. The MM-related deaths prevailed in the first 5 years of MM therapy. The appropriate monitoring and therapy interventions during the first year of MM treatment are apparently important for the long-term treatment results.